EyeGene Inc - Asset Resilience Ratio

Latest as of March 2026: 53.36%

EyeGene Inc (185490) has an Asset Resilience Ratio of 53.36% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of EyeGene Inc to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩34.53 Billion

≈ $23.40 Million USD Cash + Short-term Investments

Total Assets

₩64.70 Billion

≈ $43.85 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how EyeGene Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of EyeGene Inc.

Liquid Assets Composition Over Time

This chart breaks down EyeGene Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore EyeGene Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩34.53 Billion	53.36%
Total Liquid Assets	₩34.53 Billion	53.36%

Asset Resilience Insights

Very High Liquidity: EyeGene Inc maintains exceptional liquid asset reserves at 53.36% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

EyeGene Inc Industry Peers by Asset Resilience Ratio

Compare EyeGene Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for EyeGene Inc (2014–2025)

The table below shows the annual Asset Resilience Ratio data for EyeGene Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	51.88%	₩35.30 Billion ≈ $23.92 Million	₩68.05 Billion ≈ $46.12 Million	+3.36pp
2024-12-31	48.52%	₩31.68 Billion ≈ $21.47 Million	₩65.31 Billion ≈ $44.26 Million	-20.07pp
2023-12-31	68.58%	₩53.56 Billion ≈ $36.30 Million	₩78.10 Billion ≈ $52.93 Million	-13.14pp
2022-12-31	81.72%	₩65.69 Billion ≈ $44.52 Million	₩80.38 Billion ≈ $54.47 Million	+1.19pp
2021-12-31	80.54%	₩84.56 Billion ≈ $57.30 Million	₩104.99 Billion ≈ $71.15 Million	+6.18pp
2020-12-31	74.36%	₩33.04 Billion ≈ $22.39 Million	₩44.43 Billion ≈ $30.11 Million	-4.20pp
2019-12-31	78.56%	₩37.17 Billion ≈ $25.19 Million	₩47.31 Billion ≈ $32.06 Million	-7.96pp
2018-12-31	86.52%	₩46.76 Billion ≈ $31.69 Million	₩54.04 Billion ≈ $36.62 Million	+10.89pp
2017-12-31	75.63%	₩22.90 Billion ≈ $15.52 Million	₩30.28 Billion ≈ $20.52 Million	+9.68pp
2016-12-31	65.95%	₩12.24 Billion ≈ $8.29 Million	₩18.56 Billion ≈ $12.58 Million	-5.66pp
2015-12-31	71.61%	₩17.42 Billion ≈ $11.81 Million	₩24.33 Billion ≈ $16.49 Million	+35.39pp
2014-12-31	36.23%	₩2.01 Billion ≈ $1.36 Million	₩5.54 Billion ≈ $3.76 Million	--

pp = percentage points

About EyeGene Inc

KQ:185490 Korea Biotechnology

Market Cap

$56.56 Million

₩83.46 Billion KRW

Market Cap Rank

#21537 Global

#1270 in Korea

Share Price

₩1931.00

Change (1 day)

+0.36%

52-Week Range

₩1193.00 - ₩2600.00

All Time High

₩50300.00